137 related articles for article (PubMed ID: 30719232)
21. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.
Lorente L; Martín MM; Labarta L; Díaz C; Solé-Violán J; Blanquer J; Orbe J; Rodríguez JA; Jiménez A; Borreguero-León JM; Belmonte F; Medina JC; Llimiñana MC; Ferrer-Agüero JM; Ferreres J; Mora ML; Lubillo S; Sánchez M; Barrios Y; Sierra A; Páramo JA
Crit Care; 2009; 13(5):R158. PubMed ID: 19799791
[TBL] [Abstract][Full Text] [Related]
22. The imbalance between matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in acute pancreatitis.
Wereszczynska-Siemiatkowska U; Siemiatkowski A; Swidnicka-Siergiejko A; Mroczko B; Dabrowski A
Z Gastroenterol; 2015 Mar; 53(3):199-204. PubMed ID: 25775169
[TBL] [Abstract][Full Text] [Related]
23. Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction.
Lorente L; Martín MM; Ramos L; Cáceres JJ; Solé-Violán J; Argueso M; Jiménez A; Borreguero-León JM; Orbe J; Rodríguez JA; Páramo JA
BMC Neurol; 2015 Jul; 15():111. PubMed ID: 26162891
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study.
Wang M; Zhang Q; Zhao X; Dong G; Li C
Crit Care; 2014 Nov; 18(6):634. PubMed ID: 25407832
[TBL] [Abstract][Full Text] [Related]
25. Association of Matrix Metalloproteinases -7, -8 and -9 and TIMP -1 with Disease Severity in Acute Pancreatitis. A Cohort Study.
Nukarinen E; Lindström O; Kuuliala K; Kylänpää L; Pettilä V; Puolakkainen P; Kuuliala A; Hämäläinen M; Moilanen E; Repo H; Hästbacka J
PLoS One; 2016; 11(8):e0161480. PubMed ID: 27561093
[TBL] [Abstract][Full Text] [Related]
26. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
27. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
28. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
29. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
30. ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients.
Glazewska EK; Niczyporuk M; Lawicki S; Szmitkowski M; Zajkowska M; Donejko M; Przylipiak A
Postepy Dermatol Alergol; 2018 Apr; 35(2):167-173. PubMed ID: 29760617
[TBL] [Abstract][Full Text] [Related]
31. Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury.
Lorente L; Martín MM; López P; Ramos L; Blanquer J; Cáceres JJ; Solé-Violán J; Solera J; Cabrera J; Argueso M; Ortiz R; Mora ML; Lubillo S; Jiménez A; Borreguero-León JM; González A; Orbe J; Rodríguez JA; Páramo JA
PLoS One; 2014; 9(4):e94370. PubMed ID: 24728097
[TBL] [Abstract][Full Text] [Related]
32. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma.
Stanciu AE; Zamfir-Chiru-Anton A; Stanciu MM; Popescu CR; Gheorghe DC
Clin Lab; 2017 Oct; 63(10):1613-1620. PubMed ID: 29035450
[TBL] [Abstract][Full Text] [Related]
33. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
34. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
35. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
Cunnane G; Fitzgerald O; Beeton C; Cawston TE; Bresnihan B
Arthritis Rheum; 2001 Oct; 44(10):2263-74. PubMed ID: 11665967
[TBL] [Abstract][Full Text] [Related]
36. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
37. Expression pattern of matrix metalloproteinases-2 and -9 and their tissue inhibitors in patients with chronic inflammatory demyelinating polyneuropathy.
Cosentino G; Di Stefano V; Presti RL; Montana M; Todisco M; Gastaldi M; Cortese A; Alfonsi E; Tassorelli C; Fierro B; Caimi G; Brighina F
Neurol Sci; 2021 Oct; 42(10):4297-4300. PubMed ID: 33988800
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
39. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.
Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS
Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314
[TBL] [Abstract][Full Text] [Related]
40. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
